

World Journal of *Gastrointestinal Oncology*

World J Gastrointest Oncol 2020 June 15; 12(6): 604-704





REVIEW

- 604 Real-world evidence on adjuvant chemotherapy in older adults with stage II/III colon cancer
Batra A, Rigo R, Sheka D, Cheung WY

MINIREVIEWS

- 619 Structure and function of Septin 9 and its role in human malignant tumors
Sun J, Zheng MY, Li YW, Zhang SW

ORIGINAL ARTICLE

Retrospective Cohort Study

- 632 Low ligation has a lower anastomotic leakage rate after rectal cancer surgery
Chen JN, Liu Z, Wang ZJ, Zhao FQ, Wei FZ, Mei SW, Shen HY, Li J, Pei W, Wang Z, Yu J, Liu Q

Retrospective Study

- 642 Clinical diagnosis and management of pancreatic mucinous cystadenoma and cystadenocarcinoma: Single-center experience with 82 patients
Zhao ZM, Jiang N, Gao YX, Yin ZZ, Zhao GD, Tan XL, Xu Y, Liu R

Clinical Trials Study

- 651 Fibrin sealant for esophageal anastomosis: A phase II study
Lin YB, Fu JH, Huang Y, Hu YH, Luo KJ, Wang KX, Bella AÉ, Situ DR, Chen JY, Lin T, D'Journo XB, Novoa NM, Brunelli A, Fernando HC, Cerfolio RJ, Ismail M, Yang H,

Observational Study

- 663 Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma
Liu BJ, Gao S, Zhu X, Guo JH, Zhang X, Chen H, Wang XD, Yang RJ

- 677 Clinical significance of expression of fibrous sheath interacting protein 1 in colon cancer
Wu HY, Yang B, Geng DH

META-ANALYSIS

- 687 Timing of surgery after neoadjuvant chemoradiotherapy affects oncologic outcomes in patients with esophageal cancer
Shang QX, Yang YS, Gu YM, Zeng XX, Zhang HL, Hu WP, Wang WP, Chen LQ, Yuan Y

CASE REPORT

- 699** Immune checkpoint inhibitors induced colitis, stay vigilant: A case report
Abu Khalaf S, Albarrak A, Yousef M, Tahan V

ABOUT COVER

Editorial Board Member of *World Journal of Gastrointestinal Oncology*, Nuri Faruk Aykan, MD, Professor, Department of Medical Oncology, Istinye University, Bahcesehir Liv Hospital, Istanbul 34510, Turkey

AIMS AND SCOPE

The primary aim of *World Journal of Gastrointestinal Oncology* (WJGO, *World J Gastrointest Oncol*) is to provide scholars and readers from various fields of gastrointestinal oncology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJGO mainly publishes articles reporting research results and findings obtained in the field of gastrointestinal oncology and covering a wide range of topics including islet cell adenoma, liver cell adenoma, adenomatous polyposis coli, appendiceal neoplasms, bile duct neoplasms, biliary tract neoplasms, hepatocellular carcinoma, islet cell carcinoma, pancreatic ductal carcinoma, cecal neoplasms, colonic neoplasms, colorectal neoplasms, hereditary nonpolyposis colorectal neoplasms, common bile duct neoplasms, duodenal neoplasms, esophageal neoplasms, gallbladder neoplasms, etc.

INDEXING/ABSTRACTING

The WJGO is now indexed in Science Citation Index Expanded (also known as SciSearch®), PubMed, and PubMed Central. The 2019 edition of Journal Citation Reports® cites the 2018 impact factor for WJGO as 2.758 (5-year impact factor: 3.220), ranking WJGO as 52 among 84 journals in gastroenterology and hepatology (quartile in category Q3), and 131 among 229 journals in oncology (quartile in category Q3).

RESPONSIBLE EDITORS FOR THIS ISSUE

Responsible Electronic Editor: *Lu-Lu Qi*

Proofing Production Department Director: *Xiang Li*

Responsible Editorial Office Director: *Jin-Lai Wang*

NAME OF JOURNAL

World Journal of Gastrointestinal Oncology

ISSN

ISSN 1948-5204 (online)

LAUNCH DATE

February 15, 2009

FREQUENCY

Monthly

EDITORS-IN-CHIEF

Monjur Ahmed, Rosa M Jimenez Rodriguez, Pashtoon Kasi

EDITORIAL BOARD MEMBERS

<https://www.wjgnet.com/1948-5204/editorialboard.htm>

PUBLICATION DATE

June 15, 2020

COPYRIGHT

© 2020 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>



Structure and function of Septin 9 and its role in human malignant tumors

Jie Sun, Min-Ying Zheng, Yu-Wei Li, Shi-Wu Zhang

ORCID number: Jie Sun (0000-0001-6536-0371); Min-Ying Zheng (0000-0002-1120-8371); Yu-Wei Li (0000-0002-5488-242X); Shi-Wu Zhang (0000-0002-5052-2283).

Author contributions: All authors contributed equally to this manuscript with conception and design of the study, literature review and analysis, manuscript drafting, critical revision, and editing, and final approval of the submission.

Conflict-of-interest statement: There is no conflict of interest associated with any of the senior author or other coauthors contributed their efforts in this manuscript.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Manuscript source: Invited manuscript

Received: February 17, 2020

Peer-review started: February 17, 2020

First decision: March 24, 2020

Jie Sun, Min-Ying Zheng, Shi-Wu Zhang, Department of Pathology, Tianjin Union Medical Center, Tianjin 300121, China

Yu-Wei Li, Department of Colorectal Surgery, Tianjin Union Medical Center, Tianjin 300121, China

Corresponding author: Shi-Wu Zhang, MD, PhD, Academic Research, Chief Doctor, Director, Department of Pathology, Tianjin Union Medical Center, Jieyuan Road, Hongqiao District, Tianjin 300071, China. 30117012@nankai.edu.cn

Abstract

The treatment and prognosis of malignant tumors are closely related to the time when the tumors are diagnosed; the earlier the diagnosis of the tumor, the better the prognosis. However, most tumors are not detected in the early stages of screening and diagnosis. It is of great clinical significance to study the correlation between multiple pathogenesis of tumors and explore simple, safe, specific, and sensitive molecular indicators for early screening, diagnosis, and prognosis. The *Septin 9* (*SEPT9*) gene has been found to be associated with a variety of human diseases, and it plays a role in the development of tumors. *SEPT9* is a member of the conserved family of cytoskeletal GTPase, which consists of a P-loop-based GTP-binding domain flanked by a variable N-terminal region and a C-terminal region. *SEPT9* is involved in many biological processes such as cytokinesis, polarization, vesicle trafficking, membrane reconstruction, deoxyribonucleic acid repair, cell migration, and apoptosis. Several studies have shown that *SEPT9* may serve as a marker for early screening, diagnosis, and prognosis of some malignant tumors, and have the potential to become a new target for anti-cancer therapy. This article reviews the progress in research on the *SEPT9* gene in early screening, diagnosis, and prognosis of tumors.

Key words: Septin 9; Malignant tumor; Early diagnosis; Prognosis; Deoxyribonucleic acid methylation; Colorectal cancer

©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: The *Septin 9* (*SEPT9*) gene has been found to be associated with a variety of human diseases, and it plays a role in the development of tumors. *SEPT9* is a member of the conserved family of cytoskeletal GTPase. *SEPT9* is involved in many biological processes such as cytokinesis, polarization, vesicle trafficking, membrane reconstruction,

Revised: April 3, 2020**Accepted:** April 24, 2020**Article in press:** April 24, 2020**Published online:** June 15, 2020**P-Reviewer:** Gazouli M, Mohamed SY, Sung WW**S-Editor:** Zhang L**L-Editor:** Wang TQ**E-Editor:** Qi LL

deoxyribonucleic acid repair, cell migration, and apoptosis. Several studies have shown that SEPT9 may serve as a marker for early screening, diagnosis, and prognosis of some malignant tumors, and have the potential to become a new target for anti-cancer therapy. This article reviews the progress in research on the *SEPT9* gene in early screening, diagnosis, and prognosis of tumors.

Citation: Sun J, Zheng MY, Li YW, Zhang SW. Structure and function of Septin 9 and its role in human malignant tumors. *World J Gastrointest Oncol* 2020; 12(6): 619-631

URL: <https://www.wjgnet.com/1948-5204/full/v12/i6/619.htm>

DOI: <https://dx.doi.org/10.4251/wjgo.v12.i6.619>

INTRODUCTION

Septin 9 (SEPT9) is a cell cycle-related protein^[1] and indispensable for coordinating myosin motor proteins during cytokinesis^[2]. SEPT filaments and intermediate filaments are non-polar, which distinguishes them from actin filaments and microtubules^[1]. SEPT are a family of conserved scaffold proteins with GTP-binding protein activity which interact with each other, lead to the formation of hetero-oligomer complexes, and then polymerize into multi-functional filaments. SEPT interact with microtubule cytoskeletons, actin protein, and phospholipid membranes^[3-5] and act as scaffolds for protein-protein interactions or as diffusion barriers for protein compartmentalization during cytoskeleton formation, cell polarization, cytokinesis, cell membrane remodeling, and cell division^[6-10]. Different eukaryotes have different numbers of SEPT isoforms^[11]. To date, 13 *SEPT* genes (*SEPT1* to *SEPT12* and *SEPT14*) have been identified in mammals and they can be divided into four subgroups (*SEPT2*, *SEPT3*, *SEPT6*, and *SEPT7*). They form apolar tri-, hexa-, or octameric complexes, consisting of multiple polypeptides, due to alternative promoter usage and splicing^[3,12].

SEPT9 stabilizes the polymer and promotes the aggregation of subunits, and plays a key role in the final separation of daughter cells during cell division. Therefore, when the *SEPT9* gene is abnormally expressed or deleted, cell division may be seriously affected. The *SEPT9* gene is abnormally expressed in many malignant tumors. Tóth *et al.*^[13] reported that the *SEPT9* mRNA expression decreased during the progression of colorectal adenoma to colorectal cancer (CRC), and SEPT9 protein expression in CRC was significantly lower than that in normal epithelial cells^[13]. *SEPT9* transcript expression patterns vary in different types of malignant tumor. The expression of *SEPT9* v2, v4, v4*, and v5 isoforms was higher in cancer epithelial cells compared to normal cells^[14]. The v1 and v4 transcripts showed higher expression in ovarian cancer epithelium compared to benign and borderline tumors^[15]. The expression of v1 transcripts was higher in the normal samples than it in cancer cells, whereas *SEPT9* transcripts v2, v4, v4*, and v5 overexpression was detected in CRC epithelial cells compared to normal cells^[13]. These findings suggest that the *SEPT9* gene may play an important role in the development of malignant tumors, and it could be a new target to individualize anti-cancer treatments.

SPECIFIC STRUCTURAL CHARACTERISTICS AND BIOLOGICAL FUNCTIONS OF THE *SEPTIN 9* GENE

The *SEPT* genes are members of a conserved gene family with guanosine triphosphate activity, widely exist in eukaryotes, and were first found in the cell cycle process of budding yeast *Saccharomyces cerevisiae*^[16]. These genes produce diverse splices through variant splicing, resulting in extremely complex family members and gene functions. SEPT consist of a highly variable N-terminal domain, a central GTP-binding domain, and a C-terminal domain^[3,12]. GTP-binding domain can form linear filaments using either guanine nucleotide binding site or N- and C-terminal extensions^[1]. SEPT can assemble into heteropolymers and form higher order structures^[17].

The *SEPT9* gene is located on chromosome 17q25.3 and ubiquitous in human cells, with 18 transcript products^[18]. Members of the SEPT family have high affinity for each other and form tri-, hexa-, and octameric complexes containing multiple SEPT polypeptides. Mammalian SEPT can form an octameric complex, like SEPT9-SEPT7-SEPT6-SEPT2-SEPT2-SEPT6-SEPT7-SEPT9 (Figure 1A).




Figure 1 Specific structural characteristics and biological functions of Septin 9. A: Octamers formed by mammalian septin complexes; B: Function and role of Septin 9 in human malignant tumors. SEPT9: Septin 9; HIF-1: Hypoxia inducible factor-1; JNK: Jun N-terminal kinase.

Biological functions

SEPT9 or its complex interact with cellular proteins, like microtubules or actin microfilament, and play different physiological functions during the development of tumor (Figure 1B).

Role in cytokinesis

Cytokinesis is mainly driven by a contractile actomyosin ring (CAR), which controls membrane invagination. The CAR is recruited *via* a SEPT scaffold at division sites. The mitotic exit network, a Hippo-like kinase cascade, promotes mitotic exit, cytokinesis, and displacement of the SEPT ring from the division site. Mitotic exit network factors localize in the spindle pole body. In budding yeast, SEPT are first assembled as unorganized SEPT patches at the bud neck (constriction between mother and future daughter cells) in the G1 phase of the cell cycle. They are then assembled into the cortical SEPT ring^[19]. Microfilaments and microtubules, as the two most important cytoskeleton components during cytokinesis, regulate the assembly of SEPT fibrils. SEPT fibril assembly can be divided into two modes: Actin-dependent and actin-independent. In the former mode, the SEPT fibrils form a SEPT/anillin complex with actin fibrils, through anillin and other adaptor proteins. In this process of complex formation, GTP is not required, but the C-terminal crimp domain is connected to form a 7 nm long filamentous structure. In the latter mode, actin assembly becomes very active under the special circumstances of human cell injury. At this time, the microfilaments of the SEPT-actin complex are separated and curl to form a "C" and "O" ring structure. These two patterns of SEPT assembly play important roles in cell division^[3]. The microinjection of an affinity-purified anti-SEPT9 antibody and the use of small interfering RNAs to render cytoplasmic division defective in the early and late stages, eventually leads to the formation of binuclear cells or the failure of daughter cell separation^[20].

SEPT9 occupies the ends of mammalian octameric SEPT complex. The SEPT9 has a stable multimeric structure, promotes the polymerization of each subunit, and plays a key role in the final separation of cells during cell division^[21]. SEPT 9b binds to C-termini of both SEPT 7 and SEPT 11 through its long N-terminal extension^[22] (Figure 2A).

Role in membrane

SEPT, when self-assembled into filaments and higher-order structures, acts as a




Figure 2 Structure of the filaments containing Septins 7/9b/11 and Jun N-terminal kinase signaling pathway.

A: Structure of the filaments containing Septins 7/9b/11; B: Regulatory mechanism of Septin 9 in the development and progression of malignant tumors. HIF-1: Hypoxia inducible factor-1; JNK: Jun N-terminal kinase; EMT: Epithelial-mesenchymal transformation; MLL: Mixed-lineage leukemia.

scaffold for diverse cellular functions. This is achieved by diffusion-driven annealing to the plasma membrane^[23], which alters the cortical rigidity of migrating cells by applying membrane curvature and inducing tumor metastasis^[24]. SEPT9 levels correlate with the cell surface levels of epidermal growth factor receptors (EGFRs). SEPT9 induces tumor progression by disordering EGFRs. Plasma membrane-related SEPT9 prevents the binding of the adaptor protein, CIN85 (SH3KBP1), with the ubiquitin ligase, Cbl, thereby reducing the degradation of ubiquitin-independent EGFR^[25].

Role in microtubule

Intracellular transport is an important means of substance exchange between eukaryotic cells and their internal environment. It is also a necessary condition to maintain the physiological activities of organisms. The realization of this process requires the participation and regulation of many substances, among which, the most important regulatory factor is the major component of cytoskeleton-tubulin. SEPT filaments specifically localize with microtubules and the formation of tubulin is closely related to SEPT^[26,27]. SEPT compete with the microtubule-associated protein, MAP4, to associate with the microtubule lattice and reduce its stability^[28,29]. Microtubule-targeting agents are often used in cancer chemotherapy. SEPT9_V1 overexpression or dysregulation is associated with a poor prognosis and resistance to microtubule-targeting agents. SEPT9_V1, associated with microtubules, is strongly correlated with the susceptibility of cancer cells to 2-methoxyestradiol and paclitaxel^[30]. Some studies have shown that SEPT9 protein directly co-localizes with microtubules and spindles in HeLa cells. After treatment with the specific inhibitor of microtubule polymerization, colchicine, the structure of SEPT9 is affected and it is distributed in the cytoplasm as dots^[11].

Role in actin

SEPT control actin remodeling during cancer cell migration and invasion, prevent the depolymerization of actin by myosin and cofilin, and protect the integrity of actin filaments^[31]. Epithelial-mesenchymal transformation (EMT) is a specific biological process in which epithelial cells are transformed into cells with a mesenchymal phenotype. It plays an important role in cancer metastasis. The main characteristics of EMT are a decrease in the expression of cell adhesion molecules (such as E-cadherin), the transformation of the cytokeratin cytoskeleton into a Vimentin-based cytoskeleton, and the induction of a mesenchymal cell morphology. Through EMT, epithelial cells lose their polarity, their connection with the basement membrane, and other epithelial phenotypes and they obtain greater invasion, migration, and anti-

apoptosis abilities; become capable of degrading the extracellular matrix; and assume other interstitial phenotypes.

Knockdown of SEPT9 in metastatic cells inhibits actin cytoskeleton dynamics, induces EMT^[32], increases the activation of the Src/Vav2/RhoA pathway, and induces the proliferation of endothelial cells^[33]. Moreover, some studies have shown that the structure of filaments containing SEPTs 7/9b/11 depends on the integrity of actin filaments in REF52 cells^[22]. Cell division may be severely affected when SEPT9 gene expression is abnormal or absent. Mutations in the GTP domain of the SEPT9 gene can destabilize the cell genome and overexpression of this domain can affect SEPT9 polymer formation, ultimately leading to tumor formation^[34].

EXPRESSION OF THE SEPTIN 9 GENE IN TUMORIGENESIS AND DEVELOPMENT OF DIFFERENT MALIGNANT TUMORS

Hypoxia inducible factor-1 signaling pathway

Hypoxia inducible factor-1 (HIF-1) is a transcription factor regulating tumor cells in hypoxic environment, and consists of HIF-1-alpha and HIF-1-beta subunits. The expression of HIF-1-alpha is related to tumor invasion, metastasis, drug resistance, and prognosis. Amir *et al.*^[35] reported that the mammalian SEPT family member MSF-A (a homologue of SEPT9) and HIF-1-alpha can interact with each other. SEPT9 overexpression can inhibit ubiquitination and degradation of HIF-1-alpha, which leads to the enhancement of the transcriptional activity of HIF-1. This will in turn increase the expression of downstream genes, such as vascular endothelial growth factor, and ultimately promote tumor metastasis and invasion. High expression of vascular endothelial growth factor can promote angiogenesis of tumor tissue, which provides the basis of the proliferation and infiltration of tumors^[35].

Jun N-terminal kinase signaling pathway

Jun N-terminal kinase (JNK) is a signal transduction protein of mitogen-activated protein kinase, which is important for cell growth, division, transformation of cancer cells, and regulation of cell cycle (Figure 2B). SEPT9_v1 can maintain the activity of JNK by preventing the degradation of JNK. The retention of JNK activity can inhibit cell apoptosis and promote cell proliferation^[36].

Rho signaling pathway

SEPT protein assembly is regulated by the small GTPase superfamily. The activity of this family is regulated by GTPase-activating proteins and guanine exchange factors. Rho protein is a small protein with GTPase activity. It can regulate the expression of downstream effector molecules, thus affecting the formation of the cytoskeleton, mediating cell-cell and cell-matrix adhesion, and affecting the metastasis and invasion of tumor cells^[37]. SEPT9 is a negative upstream effector for RhoA. It is found at significantly higher levels in endothelial cells on hydrogels with low stiffness than those on hydrogels with high stiffness. Moreover, low-stiffness hydrogels can inhibit endothelial cell proliferation by inactivating integrin, resulting in an increase in SEPT9 expression and thus inhibiting the activation of the Src/Vav2/RhoA pathway^[33]. Rho activity is regulated by Rho-guanine nucleotide exchange factor (Rho GEF). SEPT-associated RhoGEF (SA-RhoGEF) can directly combine with SEPT9b and distribute along actin stress fibers. Transient transfection of SEPT9b can inhibit SA-RhoGEF-dependent Rho activity in COS7 and HeLa cells, while SA-RhoGEF transfection can alter the structure of SEPT9b fibrils^[38]. Rhetokin is the downstream effector of Rho. It can block the formation of SEPT9 fibers, thus affecting normal physiological activities, such as cell division. The conformational change in the SEPT protein induced by rhetokin is similar to the change seen during Rho activation. Thus, rhetokin may be the node connecting the SEPT protein and the Rho signaling pathway^[39].

Mitosis

During mitosis, the filaments formed by the polymerization of SEPT9 protein in interphase are dispersed in the cytoplasm in prophase and then aggregate in the cleavage groove in anaphase. High SEPT9 expression promotes genetic instability, causes mitotic spindle defects, hinders the cytoplasmic division, and leads to chromosomal segregation disorders. If SEPT9 gene expression is downregulated or absent in actively mitotic cells, cell division is impaired and cannot be completed and the spindle cannot be correctly attached, resulting in polyploidy and aneuploidy^[40-42].

DNA methylation

DNA methylation is one of the important epigenetic modifications. It refers to the transfer of a methyl group to a base by DNA methyltransferase, with S-adenosylmethionine as the methyl donor. In mammals, the methyl group is transferred to the 5th carbon atom of the cytosine in a cytosine-guanine dinucleotide (CpG) to form 5-methylcytosine^[43]. CpG islands are the main sites of DNA methylation, which is closely related to the occurrence and development of tumors. Many abnormal gene methylation processes are closely related to the pathogenesis, prognosis, and chemotherapy response of cancer. The main manifestations of these abnormalities are low total DNA methylation levels in nonpromoter regions and high methylation levels in gene promoter regions^[44]. Hypomethylation is related to transcriptional activation, resulting in increased expression of oncogenes, loss of gene imprinting, and increased chromosomal instability. By contrast, hypermethylation is related to gene expression silencing and genomic instability; reduced expression of tumor suppressor genes and DNA repair genes; and effects on normal cellular functions, such as apoptosis, DNA repair, and cell cycle regulation. *SEPT9* is a tumor suppressor gene and it has been shown to be methylated in a variety of tumors. DNA methylation is one of the most thoroughly studied epigenetic markers in eukaryotes, with studies focusing on hypomethylation of the whole genome and hypermethylation of specific repair genes and tumor suppressor genes^[45]. In vertebrates, approximately half of all gene promoters have CpG islands and abnormal hypermethylation often occurs in these regions. Abnormal methylation of the *SEPT9* gene causes abnormal gene expression and reduced gene transcription activity, leading to abnormal physiological function and finally, the development of cancer.

SEPT9 AND COLORECTAL CANCER

It is reported that hypermethylation of the CpG island in the promoter region of the *SEPT9* gene can inhibit its expression, abrogating its tumor suppressor functions, and ultimately results in the malignant tumor formation^[13]. Upon detecting the methylation status of the *SEPT9* gene in different types of colon lesions and their adjacent sites, Wasserkort *et al.*^[46] proved that hypermethylation of the *SEPT9* gene occurred in CPG island 3 of V2 transcript in CRC and adenoma epithelial cells^[46]. Hypermethylation extends from the core region to the 5' terminus in CRC tissues, but there is no hypermethylation at the 5' terminus of CPG island 3 in adenomas, which suggests that the expansion of hypermethylation may be a late event in the progression of adenoma to CRC. This characteristic of hypermethylation may be the reason for the lower sensitivity of the *SEPT9* gene methylation detection assay in adenoma than in CRC. Abnormal methylation of the *SEPT9* gene not only occurs in CRC, but also in other malignant tumors. Grützmann *et al.*^[47] compared the methylation status of the *SEPT9* gene in the plasma of patients with various malignant tumors. They showed that the positive rate of methylation in CRC patients was 72% (90/125), whereas it was only 11.5% (11/96) in non-CRC patients, which confirmed that *SEPT9* gene methylation may act as a specific diagnostic marker of CRC^[47]. Now, the peripheral blood ¹⁸SEPT9 detection has been widely used in the screening, diagnosis, prognosis, and recurrence monitoring of CRC in China because of its high specificity and sensitivity and low price.

Pathogenic Mechanism of the Septin 9 Gene in Colorectal Cancer

SEPT9 protein, being a component of the fourth cytoskeleton, can aggregate and form fibrillary microfilaments and other complexes during active cell division. It also recruits target proteins and stabilizes cytokinesis. SEPTs—Cdc3, Cdc10, Cdc11, Cdc12, and Shs1 form the bud neck ring, and induce the separation of the mother and daughter cells during cell division. The phosphorylation of SEPT9 by cyclin-dependent kinase 1 plays an important role in the disjunction of daughter cells by interacting with proline isomerase. It also affects chromosome congression and segregation during anaphase of cell division. Thus, phosphorylated SEPT9 regulates mitosis and promotes cell proliferation and survival^[48]. SEPT9 mislocalization can mediate cytokinesis failure and lead to aneuploidy, centrosome amplification, and multipolar mitoses^[40]. Elongated N-terminal tail of SEPT9 is enriched with proline residues, and interacts with actin microfilaments and microtubule^[31]. SEPT9-Spr3 and Spr28 also induce the formation of prospore membrane during sporulation^[49]. When the *SEPT9* gene in active cells was knocked out, the cells did not divide smoothly to form multinuclei, which resulted in abnormal spindle-related functions, disordered chromosome segregation, and unstable cell genome, ultimately leading to canceration of tissues^[42].

The high methylation of CpG loci of the *SEPT9* gene will block its gene expression

and result in a loss of its anti-cancer function. This DNA methylation inhibits gene expression in two ways and promotes tumorigenesis. On one hand, DNA methylation changes its conformation, making it uncondensed to bind transcription factors, and ultimately inhibits gene expression^[46]. On the other hand, methylated DNA molecules recruit and bind methylated CpG binding domain proteins. As these methylated CpG binding domain proteins continue to bind other proteins (such as histone deacetylase), eventually it forms a compact and inactive abnormal chromatin, which inhibits gene expression.

Autophagy, a regulatory cellular mechanism, prevents malignant transformation of cells by reducing oxidative stress, eliminating oncogene proteins, and maintaining genomic stability, thereby exerting its anti-cancer potential^[50]. Studies have shown that cell autophagy inhibits the occurrence of CRC^[51]. SEPT protein complex participates in cell autophagy^[52,53]. Methylation of the *SEPT9* gene inhibits the expression of SEPT9 protein, decreasing cell autophagy function, and thereby, promotes the occurrence and development of CRC. For example, in microsatellite-unstable CRC, frameshift mutation of UVRAG counteracts its anti-tumor function of inducing autophagy and DNA repair, which in turn promotes tumorigenesis, epithelial-mesenchymal transformation, and metastasis^[27,54,55].

Application of Septin 9 in Early Screening, Diagnosis, and Prognosis of Colorectal Cancer

Since 2008, different research groups have published a series of clinical data on screening early stage CRC by detecting *SEPT9* gene methylation. Since the second generation detection kit EpiProColon 2.0 (German Epigenomics AG) was used, its sensitivity has increased to 79.3%-95.6% and specificity has reached 84.8%-98.9%^[56]. In the CRC screening process, the high specificity of screening methods is conducive for excluding non-cancer samples to avoid unnecessary colonoscopy, and the high-risk population who may miss diagnosis can be compensated by regular fecal occult blood test review^[57]. For screening of precancerous lesions by *SEPT9* methylation detection, the sensitivity is 11%-19% and specificity is 85%-94% in adenomas. For polyps, the sensitivity is 3%-8% and specificity is 90%-97%. The sensitivity is low both in adenomas and polyps, suggesting that detection of *SEPT9* gene methylation has limited diagnostic value for precancerous lesions of CRC^[58]. The positive rates of *SEPT9* gene methylation in peripheral blood of patients with stages I, II, III, and IV CRC were 45%, 70%, 76%, and 79%, respectively, which indicated that *SEPT9* gene methylation detection still had appreciated value for detecting early CRC, and can provide a basis for diagnosis^[59]. The positive rate of methylation increased with the progression of CRC, which may be related to the increase of necrosis and apoptosis of primary tumor cells and the increase of methylated *SEPT9* gene DNA released into peripheral blood. A study observed the changes in plasma *SEPT9* gene methylation levels in CRC patients before and after radical surgery. During the follow-up period of approximately 4 mo, 8 out of 9 patients with positive preoperative methylation turned negative (88.9%). Survival analysis showed that there was a significant negative correlation between SEPT9 methylation levels and disease-free survival after CRC surgery^[60]. Although the sample size of that study was small, it indicated that *SEPT9* gene methylation in peripheral blood can be used as a monitoring index for recurrence after CRC surgery. Whether this index can be used as an evaluation index for the efficacy of CRC radiotherapy and chemotherapy remains to be further explored.

Studies have compared the diagnostic efficacy of *SEPT9* gene methylation detection and fecal immunoassay test (FIT) alone or combined in CRC screening. The results showed that the sensitivity and specificity of SEPT9 and FIT alone were 73.3%-81.5% and 53.8%-88.9%, and 81.5%-95.3% and 54.1%-97.4%, respectively. The sensitivity and specificity of the combined diagnosis of SEPT9 and fecal occult blood test were 88.7%-97.8% and 52.9%-78.8%, respectively. SEPT9 methylation was superior to FIT in sensitivity, and joint detection was helpful to further improve sensitivity^[61]. Glycoprotein markers for CRC screening include CEA, CA19-9, CA125, CA724, and CA242. The sensitivity and specificity of the diagnostic panel consisting of CEA, CA19-9, CA242, CA211, and CA724 were 83% and 95%, respectively, which were similar to those of detection of *SEPT9* gene methylation in peripheral blood. The sensitivity and specificity of the most commonly used single serum CEA were lower than those of *SEPT9* gene methylation^[62-64]. Colonoscopy biopsy combined with pathological diagnosis is the golden standard for the diagnosis of CRC. In recent years, endoscopic treatment of colorectal tumors has become more developed. The application of endoscopic surgery such as endoscopic mucosal resection and endoscopic submucosal dissection in the treatment of precancerous lesions has gradually increased. However, colonoscopy has few limitations. Large-scale screening by colonoscopy can consume a lot of medical resources. It requires thorough bowel

preparation to ensure a clear visual field. Moreover, contraindications and complications risk can occur during colonoscopy. All these limitations may lead to poor patient compliance. Therefore, the consensus of early CRC screening process is recommended by the clinical experts in China in order to stratify the risk of screening population. FIT and/or *SEPT9* gene methylation detection can be used for low-risk population, and colonoscopy can be used for high-risk population^[65].

A large number of clinical data confirmed that the detection of *SEPT9* gene methylation in peripheral blood has a high sensitivity and specificity for the diagnosis of CRC. It can be used for early CRC screening. The results are not affected by sex and tumor location, and can guide the selection of follow-up screening methods and improve the compliance of the population to colonoscopy. Our previous study showed that methylation of *SEPT9* is useful for the screening, diagnosis, and recurrence monitoring of CRC, and methylation of *SEPT9* is associated with TNM category, Dukes stage, gross tumor volume, and mismatch repair-deficiency status^[63]. Another study also showed that patients with high levels of methylation of *SEPT9* had a tendency toward lower overall survival, which demonstrated that methylation of *SEPT9* may be a useful biomarker for the prognosis of CRC^[66].

SEPTIN 9 AND BREAST CANCER

The *SEPT9* gene is also closely related to the occurrence and development of breast cancer. The expression level of the *SEPT9* gene had significantly increased in mice with breast cancer induced by transgenic technology. Thsp1 and Bax-mediated apoptosis decreased in human breast cancer and breast cancer cell lines with high *SEPT9* expression. Silencing *SEPT9* expression reversed this effect^[67], suggesting that the inhibitory effect of *SEPT9* on apoptosis could promote the progression of breast cancer. The expression of *SEPT9* in human breast cancer cell lines MCF10A and MCF-7 and breast cancer tissues was high. Overexpression of *SEPT9* could accelerate cell proliferation, increase invasiveness of cancer tissues, and cause chromosomal abnormalities^[68]. In addition, the expression of *SEPT9* isoforms in different tumors was also different. The main isoform closely related to breast cancer is *SEPT9-v1*. Overexpression of *SEPT9-v1* promoted the transformation of breast epithelial cells to breast stromal cells, thus promoting the development of breast cancer. Few studies reported that *SEPT9-v3* was closely related to breast cancer and its expression was regulated by methylation^[14]. Methylation can decrease the expression of *SEPT9-v3*, while demethylation can increase the levels of *SEPT9-v3* protein and mRNA. However, a study found that *SEPT9-v2* was also related to breast cancer, and the *SEPT9_v2* promoter hypermethylation was found in 67% of breast cancer cell lines and 53% of breast cancer tissue, but not in normal breast tissue^[69]. Other studies showed increased transcription of four variants of the *SEPT9* gene, v1, v3, v6, and v7, in breast cancer tissues^[70]. In addition, a study also found that *SEPT9* and *SEPT2*, *SEPT8*, and *SEPT11* were involved in the mechanism of paclitaxel resistance in human breast cancer cell lines by regulating cellular microenvironment^[71]. The overexpression of the *SEPT9-i1* isoform enhanced cell resistance to paclitaxel, which was further enhanced by microtubule polyglutamylation^[72]. So far, several studies have confirmed the close relationship between *SEPT9* and breast cancer. This provides a new idea for searching tumor markers for early screening and diagnosis of breast cancer, as well as clues for finding new therapeutic targets for breast cancer.

SEPTIN 9 AND HEMATOLOGICAL TUMORS

In a large number of studies on hematological malignancy, gene fusion was often found in leukemia patients. Mixed-lineage leukemia (*MLL*) gene rearrangement is very common in leukemia^[73]. The N-terminal base sequence of the *MLL* gene and *SEPT9* gene can fuse in frame and produce chimeric protein^[74]. *SEPT* family genes such as *SEPT2*, *SEPT5*, *SEPT6*, *SEPT9*, and *SEPT11* can also fuse with *MLL*. Diseases associated with the fusion of the *MLL* and *SEPT9* genes include acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome, but their mechanism of action is not yet clear. In 2007, Kreuziger *et al*^[75] reported the fusion of the *MLL* gene and *SEPT9* gene in a patient with myelodysplastic syndrome^[75]. In one case study of acute monocytic leukemia, t(11;17)(q23;q25) appeared, accompanied by fusion of the *SEPT9* gene and *MLL* gene^[76]. Another study found that exon 8 at the 3' end of the *MLL* gene was fused with exon 2 and exon 3 at the 5' end of the *SEPT9* gene in patients with acute myeloid leukemia^[77]. In addition, *AML1* gene amplification and 17q25 deletion were also found in leukemia patients^[78]. In a study involving 45

patients with leukemia, *MLL* gene rearrangements were found to be associated with *SEPT9* gene^[79]. A study also showed that patients with acute megakaryoblastic leukemia and t(11;17)(q23;25) had a *KMT2A-SEPT9* fusion^[80]. Overall, these studies have shown that *SEPT9* gene is closely related to the occurrence and development of leukemia, and its fusion with the *MLL* gene may be one of the pathogeneses of leukemia. And in other hematological tumors, like T-cell lymphomas, study found that murine retrovirus SL3-3 was integrated into the *SEPT9* gene locus^[81].

SEPTIN 9 AND HEAD AND NECK SQUAMOUS CELL CARCINOMA

In a study, five highly methylated genes, including *SEPT9*, were detected in head and neck squamous cell carcinomas by restriction marker genome scanning^[82]. This suggests that the *SEPT9* gene is associated with head and neck tumors. It was also found that the expression of *SEPT9-v1* was higher in head and neck squamous cell carcinoma than in normal tissues. The higher the expression of *SEPT9-v1*, the higher the stage of head and neck squamous cell carcinoma^[83]. A cohort study by Schrock *et al.*^[84] showed that detection of plasma methylated *SEPT9* is a valuable method for early diagnosis and monitoring of head and neck squamous cell carcinoma^[84]. Hence, these studies suggest that *SEPT9* may also be a marker for head and neck squamous cell carcinoma.

OTHER MALIGNANT TUMORS

Studies have confirmed that *SEPT9* is also associated with various kinds of tumors. The *SEPT9* gene is closely related to ovarian cancer^[15]. Detection of *SEPT9* expression in benign, borderline, and malignant serous and mucinous ovarian tumors by fluorescent quantitative PCR showed that *SEPT9-v1* and *SEPT9-v4* were significantly increased in borderline ovarian tumors, but not in benign ovarian tumors and ovarian cancer. At the same time, the high expression of *SEPT9-v1* transcript coincided with the high expression of *SEPT9-v4* transcripts, and the ratio between them was related to the phenotype of borderline and malignant tumors. These results suggested that the high expression of *SEPT9-v1* and *SEPT9-v4* may be associated with the occurrence of borderline ovarian tumors. The mean level of plasma *SEPT9* in epithelial ovarian carcinoma patients was significantly higher than that in healthy women. The mean level of plasma *SEPT9* in epithelial ovarian cancer patients with a tumor family history or distant metastases was significantly higher than that of other patients^[85].

The methylation of *SEPT9* promoter region was found in lung cancer patients, which resulted in a decrease in the expression of *SEPT9* protein^[86]. This was similar to the increased methylation of the *SEPT9* gene in patients with colorectal cancer. A study involving 70 lung cancer patients and 100 healthy people explored the relationship between lung cancer and *SEPT9*. The results showed that the positive rate of methylated *SEPT9* gene in peripheral blood of the lung cancer group was much higher than that of the control group. This study suggests that detection of methylated *SEPT9* gene level in peripheral blood may have some clinical significance in early diagnosis of lung cancer^[87].

Li *et al.*^[88] analyzed the expression level of *SEPT9* in 102 cases of gastric cancer and their adjacent tissues by tissue microarray and immunohistochemical staining, and studied the relationship between *SEPT9* and the degree of differentiation of cancer. The results showed that the expression of *SEPT9* was higher in gastric cancer tissues than in the adjacent tissues and related to the degree of differentiation of cancer^[88].

AREAS FOR FUTURE RESEARCH

DNA methylation may be one of the mechanisms regulating the differential expression of *SEPT9* transcripts. DNA methylation is an important epigenetic modification, and CpG islands are the main sites of DNA methylation. Abnormal gene methylations have been observed in different kinds of malignant tumor. DNA methylation is closely related to the development, progression, occurrence, prognosis, and chemotherapy response of malignant tumors^[43,44]. DNA methylation includes hypermethylation and hypomethylation. It is believed that hypermethylation leads to gene silencing and decreased protein expression, while hypomethylation leads to the activation of genes and increased protein expression. Detection of methylation level of

the *SEPT9* gene in peripheral blood has a high sensitivity and specificity for the diagnosis of some malignant tumors, especially CRC, and the detection result is not affected by the patient's gender and the location of the tumor. Furthermore, detection of methylation level of the *SEPT9* gene in peripheral blood by PCR can be used to assess the risk of some malignant tumor initiation and relapse, and can be widely used in clinic because of the use of non-fasting, easy-to-obtain blood samples, noninvasiveness, and good patient compliance^[56,89].

CONCLUSION

It has been more than 40 years since the initial discovery of the *SEPT* gene in yeast. During this period, there has been much in-depth research on SEPTs. According to their different tissue expression patterns and different proteins they interact with, members of the *SEPT* gene family can perform different cellular functions. However, due to the nature of the SEPT family structure and the complexity of its members, the detailed physiological functions of SEPTs require further study. *SEPT* gene expression is strictly controlled to maintain the correct assembly of filaments and normal cellular functions. However, if gene mutations result in changes to SEPT proteins or their expression levels, this may lead to the development of disease.

As reviewed above, a large number of studies have confirmed the correlation between the *SEPT9* gene and a diverse range of tumor types. The expression levels, mutations, and functions of the *SEPT9* gene are different in different tumors. Genetic and epigenetic changes in the *SEPT9* gene are linked to proliferation, autophagy, angiogenesis, cell invasion, chromosomal instability, microsatellite instability, resistance to anti-cancer drugs, and the induction of tumor growth by the cancer-associated microenvironment. Several clinical trials have confirmed that methylation of the *SEPT9* gene is a specific biological marker for some tumors. However, further studies are required to determine the specific mechanism whereby the regulation of *SEPT9* affects tumorigenesis and tumor progression and to determine the correlation between *SEPT9* and other pathogenic mechanisms. In the future, with ongoing research, a novel role for *SEPT9* may be identified in the early screening, diagnosis, targeted therapy, prognosis, and recurrence monitoring of different cancers.

REFERENCES

- 1 Mostowy S, Cossart P. Septins: the fourth component of the cytoskeleton. *Nat Rev Mol Cell Biol* 2012; **13**: 183-194 [PMID: 22314400 DOI: 10.1038/nrm3284]
- 2 El Amine N, Kechad A, Jananji S, Hickson GR. Opposing actions of septins and Sticky on Anillin promote the transition from contractile to midbody ring. *J Cell Biol* 2013; **203**: 487-504 [PMID: 24217622 DOI: 10.1083/jcb.201305053]
- 3 Kinoshita M, Field CM, Coughlin ML, Straight AF, Mitchison TJ. Self- and actin-templated assembly of Mammalian septins. *Dev Cell* 2002; **3**: 791-802 [PMID: 12479805 DOI: 10.1016/s1534-5807(02)00366-0]
- 4 Bowen JR, Hwang D, Bai X, Roy D, Spiliotis ET. Septin GTPases spatially guide microtubule organization and plus end dynamics in polarizing epithelia. *J Cell Biol* 2011; **194**: 187-197 [PMID: 21788367 DOI: 10.1083/jcb.201102076]
- 5 Bertin A, McMurray MA, Thai L, Garcia G, Votin V, Grob P, Allyn T, Thorner J, Nogales E. Phosphatidylinositol-4,5-bisphosphate promotes budding yeast septin filament assembly and organization. *J Mol Biol* 2010; **404**: 711-731 [PMID: 20951708 DOI: 10.1016/j.jmb.2010.10.002]
- 6 Dolat L, Hu Q, Spiliotis ET. Septin functions in organ system physiology and pathology. *Biol Chem* 2014; **395**: 123-141 [PMID: 24114910 DOI: 10.1515/hsz-2013-0233]
- 7 Macara IG, Baldarelli R, Field CM, Glotzer M, Hayashi Y, Hsu SC, Kennedy MB, Kinoshita M, Longtine M, Low C, Maltais LJ, McKenzie L, Mitchison TJ, Nishikawa T, Noda M, Petty EM, Peifer M, Pringle JR, Robinson PJ, Roth D, Russell SE, Stuhlmann H, Tanaka M, Tanaka T, Trimble WS, Ware J, Zeleznik-Le NJ, Zieger B. Mammalian septins nomenclature. *Mol Biol Cell* 2002; **13**: 4111-4113 [PMID: 12475938 DOI: 10.1091/mbc.e02-07-0438]
- 8 Longtine MS, DeMarini DJ, Valencik ML, Al-Awar OS, Fares H, De Virgilio C, Pringle JR. The septins: roles in cytokinesis and other processes. *Curr Opin Cell Biol* 1996; **8**: 106-119 [PMID: 8791410 DOI: 10.1016/s0955-0674(96)80054-8]
- 9 Neubauer K, Zieger B. The Mammalian Septin Interactome. *Front Cell Dev Biol* 2017; **5**: 3 [PMID: 28224124 DOI: 10.3389/fcell.2017.00003]
- 10 Karasmanis EP, Hwang D, Nakos K, Bowen JR, Angelis D, Spiliotis ET. A Septin Double Ring Controls the Spatiotemporal Organization of the ESCRT Machinery in Cytokinetic Abscission. *Curr Biol* 2019; **29**: 2174-2182.e7 [PMID: 31204162 DOI: 10.1016/j.cub.2019.05.050]
- 11 Weirich CS, Erzberger JP, Barral Y. The septin family of GTPases: architecture and dynamics. *Nat Rev Mol Cell Biol* 2008; **9**: 478-489 [PMID: 18478031 DOI: 10.1038/nrm2407]
- 12 Kinoshita M. Assembly of mammalian septins. *J Biochem* 2003; **134**: 491-496 [PMID: 14607974 DOI: 10.1093/jb/mvg182]
- 13 Tóth K, Galamb O, Spisák S, Wichmann B, Sipos F, Valcz G, Leiszter K, Molnár B, Tulassay Z. The influence of methylated septin 9 gene on RNA and protein level in colorectal cancer. *Pathol Oncol Res* 2011; **17**: 503-509 [PMID: 21267688 DOI: 10.1007/s12253-010-9338-7]
- 14 Connolly D, Yang Z, Castaldi M, Simmons N, Oktay MH, Coniglio S, Fazzari MJ, Verdier-Pinard P,

- Montagna C. Septin 9 isoform expression, localization and epigenetic changes during human and mouse breast cancer progression. *Breast Cancer Res* 2011; **13**: R76 [PMID: [21831286](#) DOI: [10.1186/bcr2924](#)]
- 15 **Scott M**, McCluggage WG, Hillan KJ, Hall PA, Russell SE. Altered patterns of transcription of the septin gene, SEPT9, in ovarian tumorigenesis. *Int J Cancer* 2006; **118**: 1325-1329 [PMID: [16161048](#) DOI: [10.1002/ijc.21486](#)]
- 16 **Hartwell LH**. Genetic control of the cell division cycle in yeast. IV. Genes controlling bud emergence and cytokinesis. *Exp Cell Res* 1971; **69**: 265-276 [PMID: [4950437](#) DOI: [10.1016/0014-4827\(71\)90223-0](#)]
- 17 **Abbey M**, Hakim C, Anand R, Lafera J, Schambach A, Kispert A, Taft MH, Kaever V, Kotlyarov A, Gaestel M, Menon MB. GTPase domain driven dimerization of SEPT7 is dispensable for the critical role of septins in fibroblast cytokinesis. *Sci Rep* 2016; **6**: 20007 [PMID: [26818767](#) DOI: [10.1038/srep20007](#)]
- 18 **McIlhatton MA**, Burrows JF, Donaghy PG, Chanduloy S, Johnston PG, Russell SE. Genomic organization, complex splicing pattern and expression of a human septin gene on chromosome 17q25.3. *Oncogene* 2001; **20**: 5930-5939 [PMID: [11593400](#) DOI: [10.1038/sj.onc.1204752](#)]
- 19 **Tamborini D**, Juanes MA, Ibanes S, Rancati G, Piatti S. Recruitment of the mitotic exit network to yeast centrosomes couples septin displacement to actomyosin constriction. *Nat Commun* 2018; **9**: 4308 [PMID: [30333493](#) DOI: [10.1038/s41467-018-06767-0](#)]
- 20 **Estey MP**, Di Ciano-Oliveira C, Froese CD, Bejide MT, Trimble WS. Distinct roles of septins in cytokinesis: SEPT9 mediates midbody abscission. *J Cell Biol* 2010; **191**: 741-749 [PMID: [21059847](#) DOI: [10.1083/jcb.201006031](#)]
- 21 **Kim MS**, Froese CD, Estey MP, Trimble WS. SEPT9 occupies the terminal positions in septin octamers and mediates polymerization-dependent functions in abscission. *J Cell Biol* 2011; **195**: 815-826 [PMID: [22123865](#) DOI: [10.1083/jcb.201106131](#)]
- 22 **Nagata K**, Asano T, Nozawa Y, Inagaki M. Biochemical and cell biological analyses of a mammalian septin complex, Sept7/9b/11. *J Biol Chem* 2004; **279**: 55895-55904 [PMID: [15485874](#) DOI: [10.1074/jbc.M406153200](#)]
- 23 **Bridges AA**, Zhang H, Mehta SB, Occhipinti P, Tani T, Gladfelter AS. Septin assemblies form by diffusion-driven annealing on membranes. *Proc Natl Acad Sci USA* 2014; **111**: 2146-2151 [PMID: [24469790](#) DOI: [10.1073/pnas.1314138111](#)]
- 24 **Tanaka-Takiguchi Y**, Kinoshita M, Takiguchi K. Septin-mediated uniform bracing of phospholipid membranes. *Curr Biol* 2009; **19**: 140-145 [PMID: [19167227](#) DOI: [10.1016/j.cub.2008.12.030](#)]
- 25 **Diesenberg K**, Beerbaum M, Fink U, Schmieder P, Krauss M. SEPT9 negatively regulates ubiquitin-dependent downregulation of EGFR. *J Cell Sci* 2015; **128**: 397-407 [PMID: [25472714](#) DOI: [10.1242/jcs.162206](#)]
- 26 **Surka MC**, Tsang CW, Trimble WS. The mammalian septin MSF localizes with microtubules and is required for completion of cytokinesis. *Mol Biol Cell* 2002; **13**: 3532-3545 [PMID: [12388755](#) DOI: [10.1091/mbc.e02-01-0042](#)]
- 27 **Nagata K**, Kawajiri A, Matsui S, Takagishi M, Shiromizu T, Saitoh N, Izawa I, Kiyono T, Itoh TJ, Hotani H, Inagaki M. Filament formation of MSF-A, a mammalian septin, in human mammary epithelial cells depends on interactions with microtubules. *J Biol Chem* 2003; **278**: 18538-18543 [PMID: [12626509](#) DOI: [10.1074/jbc.M205246200](#)]
- 28 **Kremer BE**, Haystead T, Macara IG. Mammalian septins regulate microtubule stability through interaction with the microtubule-binding protein MAP4. *Mol Biol Cell* 2005; **16**: 4648-4659 [PMID: [16093351](#) DOI: [10.1091/mbc.e05-03-0267](#)]
- 29 **Spiliotis ET**, Hunt SJ, Hu Q, Kinoshita M, Nelson WJ. Epithelial polarity requires septin coupling of vesicle transport to polyglutamylated microtubules. *J Cell Biol* 2008; **180**: 295-303 [PMID: [18209106](#) DOI: [10.1083/jcb.200710039](#)]
- 30 **Amir S**, Mabjeesh NJ. SEPT9_v1 protein expression is associated with human cancer cell resistance to microtubule-disrupting agents. *Cancer Biol Ther* 2007; **6**: 1926-1931 [PMID: [18075300](#) DOI: [10.4161/cbt.6.12.4971](#)]
- 31 **Smith C**, Dolat L, Angelis D, Forgacs E, Spiliotis ET, Galkin VE. Septin 9 Exhibits Polymorphic Binding to F-Actin and Inhibits Myosin and Cofilin Activity. *J Mol Biol* 2015; **427**: 3273-3284 [PMID: [26297986](#) DOI: [10.1016/j.jmb.2015.07.026](#)]
- 32 **Shankar J**, Messenberg A, Chan J, Underhill TM, Foster LJ, Nabi IR. Pseudopodial actin dynamics control epithelial-mesenchymal transition in metastatic cancer cells. *Cancer Res* 2010; **70**: 3780-3790 [PMID: [20388789](#) DOI: [10.1158/0008-5472.CAN-09-4439](#)]
- 33 **Yeh YT**, Hur SS, Chang J, Wang KC, Chiu JJ, Li YS, Chien S. Matrix stiffness regulates endothelial cell proliferation through septin 9. *PLoS One* 2012; **7**: e46889 [PMID: [23118862](#) DOI: [10.1371/journal.pone.0046889](#)]
- 34 **Chacko AD**, Hyland PL, McDade SS, Hamilton PW, Russell SH, Hall PA. SEPT9_v4 expression induces morphological change, increased motility and disturbed polarity. *J Pathol* 2005; **206**: 458-465 [PMID: [15902694](#) DOI: [10.1002/path.1794](#)]
- 35 **Amir S**, Wang R, Matzkin H, Simons JW, Mabjeesh NJ. MSF-A interacts with hypoxia-inducible factor-1alpha and augments hypoxia-inducible factor transcriptional activation to affect tumorigenicity and angiogenesis. *Cancer Res* 2006; **66**: 856-866 [PMID: [16424018](#) DOI: [10.1158/0008-5472.CAN-05-2738](#)]
- 36 **Gonzalez ME**, Makarova O, Peterson EA, Privette LM, Petty EM. Up-regulation of SEPT9_v1 stabilizes c-Jun-N-terminal kinase and contributes to its pro-proliferative activity in mammary epithelial cells. *Cell Signal* 2009; **21**: 477-487 [PMID: [19071215](#) DOI: [10.1016/j.cellsig.2008.11.007](#)]
- 37 **Rath N**, Olson MF. Rho-associated kinases in tumorigenesis: re-considering ROCK inhibition for cancer therapy. *EMBO Rep* 2012; **13**: 900-908 [PMID: [22964758](#) DOI: [10.1038/embor.2012.127](#)]
- 38 **Nagata K**, Inagaki M. Cytoskeletal modification of Rho guanine nucleotide exchange factor activity: identification of a Rho guanine nucleotide exchange factor as a binding partner for Sept9b, a mammalian septin. *Oncogene* 2005; **24**: 65-76 [PMID: [15558029](#) DOI: [10.1038/sj.onc.1208101](#)]
- 39 **Ito H**, Iwamoto I, Morishita R, Nozawa Y, Narumiya S, Asano T, Nagata K. Possible role of Rho/Rhotekin signaling in mammalian septin organization. *Oncogene* 2005; **24**: 7064-7072 [PMID: [16007136](#) DOI: [10.1038/sj.onc.1208862](#)]
- 40 **Cortez BA**, Rezende-Teixeira P, Redick S, Doxsey S, Machado-Santelli GM. Multipolar mitosis and aneuploidy after chrysotile treatment: a consequence of abscission failure and cytokinesis regression. *Oncotarget* 2016; **7**: 8979-8992 [PMID: [26788989](#) DOI: [10.18632/oncotarget.6924](#)]
- 41 **Peterson EA**, Stanbery L, Li C, Kocak H, Makarova O, Petty EM. SEPT9_i1 and genomic instability: mechanistic insights and relevance to tumorigenesis. *Genes Chromosomes Cancer* 2011; **50**: 940-949 [PMID: [21910160](#) DOI: [10.1002/gcc.20916](#)]

- 42 **Füchtbauer A**, Lassen LB, Jensen AB, Howard J, Quiroga Ade S, Warming S, Sørensen AB, Pedersen FS, Füchtbauer EM. Septin9 is involved in septin filament formation and cellular stability. *Biol Chem* 2011; **392**: 769-777 [PMID: [21824004](#) DOI: [10.1515/BC.2011.088](#)]
- 43 **Weber M**, Hellmann I, Stadler MB, Ramos L, Pääbo S, Rebhan M, Schübeler D. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. *Nat Genet* 2007; **39**: 457-466 [PMID: [17334365](#) DOI: [10.1038/ng1990](#)]
- 44 **Hinoue T**, Weisenberger DJ, Lange CP, Shen H, Byun HM, Van Den Berg D, Malik S, Pan F, Noushmehr H, van Dijk CM, Tollenaar RA, Laird PW. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. *Genome Res* 2012; **22**: 271-282 [PMID: [21659424](#) DOI: [10.1101/gr.117523.110](#)]
- 45 **Yang X**, Lay F, Han H, Jones PA. Targeting DNA methylation for epigenetic therapy. *Trends Pharmacol Sci* 2010; **31**: 536-546 [PMID: [20846732](#) DOI: [10.1016/j.tips.2010.08.001](#)]
- 46 **Wasserkort R**, Kalmar A, Valcz G, Spisak S, Krispin M, Toth K, Tulassay Z, Sledziewski AZ, Molnar B. Aberrant septin 9 DNA methylation in colorectal cancer is restricted to a single CpG island. *BMC Cancer* 2013; **13**: 398 [PMID: [23988185](#) DOI: [10.1186/1471-2407-13-398](#)]
- 47 **Grützmann R**, Molnar B, Pilarsky C, Habermann JK, Schlag PM, Saeger HD, Miehlke S, Stolz T, Model F, Roblick UJ, Bruch HP, Koch R, Liebenberg V, Devos T, Song X, Day RH, Sledziewski AZ, Lofton-Day C. Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay. *PLoS One* 2008; **3**: e3759 [PMID: [19018278](#) DOI: [10.1371/journal.pone.0003759](#)]
- 48 **Estey MP**, Di Ciano-Oliveira C, Froese CD, Fung KY, Steels JD, Litchfield DW, Trimble WS. Mitotic regulation of SEPT9 protein by cyclin-dependent kinase 1 (Cdk1) and Pin1 protein is important for the completion of cytokinesis. *J Biol Chem* 2013; **288**: 30075-30086 [PMID: [23990466](#) DOI: [10.1074/jbc.M113.474932](#)]
- 49 **Barve G**, Sanyal P, Manjithaya R. Septin localization and function during autophagy. *Curr Genet* 2018; **64**: 1037-1041 [PMID: [29651536](#) DOI: [10.1007/s00294-018-0834-8](#)]
- 50 **Galluzzi L**, Pietrocola F, Bravo-San Pedro JM, Amaravadi RK, Baehrecke EH, Cecconi F, Codogno P, Debnath J, Gewirtz DA, Karantza V, Kimmelman A, Kumar S, Levine B, Maiuri MC, Martin SJ, Penninger J, Piacentini M, Rubinsztein DC, Simon HU, Simonsen A, Thorburn AM, Velasco G, Ryan KM, Kroemer G. Autophagy in malignant transformation and cancer progression. *EMBO J* 2015; **34**: 856-880 [PMID: [25712477](#) DOI: [10.15252/embj.201490784](#)]
- 51 **Rybstein MD**, Bravo-San Pedro JM, Kroemer G, Galluzzi L. The autophagic network and cancer. *Nat Cell Biol* 2018; **20**: 243-251 [PMID: [29476153](#) DOI: [10.1038/s41556-018-0042-2](#)]
- 52 **Krokowski S**, Mostowy S. Bacterial cell division is recognized by the septin cytoskeleton for restriction by autophagy. *Autophagy* 2019; **15**: 937-939 [PMID: [30857451](#) DOI: [10.1080/15548627.2019.1586499](#)]
- 53 **Kast DJ**, Dominguez R. WHAMM links actin assembly via the Arp2/3 complex to autophagy. *Autophagy* 2015; **11**: 1702-1704 [PMID: [26291929](#) DOI: [10.1080/15548627.2015.1073434](#)]
- 54 **He S**, Liang C. Frameshift mutation of UVRAG: Switching a tumor suppressor to an oncogene in colorectal cancer. *Autophagy* 2015; **11**: 1939-1940 [PMID: [26327192](#) DOI: [10.1080/15548627.2015.1086523](#)]
- 55 **Barve G**, Sridhar S, Aher A, Sahani MH, Chinchwadkar S, Singh S, K N L, McMurray MA, Manjithaya R. Septins are involved at the early stages of macroautophagy in *S. cerevisiae*. *J Cell Sci* 2018; **131** [PMID: [29361537](#) DOI: [10.1242/jcs.209098](#)]
- 56 **Tóth K**, Sipos F, Kalmár A, Patai AV, Wichmann B, Stoehr R, Golcher H, Schellerer V, Tulassay Z, Molnár B. Detection of methylated SEPT9 in plasma is a reliable screening method for both left- and right-sided colon cancers. *PLoS One* 2012; **7**: e46000 [PMID: [23049919](#) DOI: [10.1371/journal.pone.0046000](#)]
- 57 **Song L**, Yu H, Jia J, Li Y. A systematic review of the performance of the SEPT9 gene methylation assay in colorectal cancer screening, monitoring, diagnosis and prognosis. *Cancer Biomark* 2017; **18**: 425-432 [PMID: [28128742](#) DOI: [10.3233/CBM-160321](#)]
- 58 **Nian J**, Sun X, Ming S, Yan C, Ma Y, Feng Y, Yang L, Yu M, Zhang G, Wang X. Diagnostic Accuracy of Methylated SEPT9 for Blood-based Colorectal Cancer Detection: A Systematic Review and Meta-Analysis. *Clin Transl Gastroenterol* 2017; **8**: e216 [PMID: [28102859](#) DOI: [10.1038/ctg.2016.66](#)]
- 59 **Song L**, Li Y. SEPT9: A Specific Circulating Biomarker for Colorectal Cancer. *Adv Clin Chem* 2015; **72**: 171-204 [PMID: [26471083](#) DOI: [10.1016/bs.acc.2015.07.004](#)]
- 60 **Lee HS**, Hwang SM, Kim TS, Kim DW, Park DJ, Kang SB, Kim HH, Park KU. Circulating methylated septin 9 nucleic Acid in the plasma of patients with gastrointestinal cancer in the stomach and colon. *Transl Oncol* 2013; **6**: 290-296 [PMID: [23730408](#) DOI: [10.1593/tlo.13118](#)]
- 61 **Johnson DA**, Barclay RL, Mergener K, Weiss G, König T, Beck J, Potter NT. Plasma Septin9 versus fecal immunochemical testing for colorectal cancer screening: a prospective multicenter study. *PLoS One* 2014; **9**: e98238 [PMID: [24901436](#) DOI: [10.1371/journal.pone.0098238](#)]
- 62 **Song L**, Yu H, Jia J, Li Y. A systematic review of the performance of the SEPT9 gene methylation assay in colorectal cancer screening, monitoring, diagnosis and prognosis. *Cancer Biomark* 2017; **18**: 425-432 [PMID: [28128742](#) DOI: [10.3233/CBM-160321](#)]
- 63 **Sun J**, Fei F, Zhang M, Li Y, Zhang X, Zhu S, Zhang S. The role of mSEPT9 in screening, diagnosis, and recurrence monitoring of colorectal cancer. *BMC Cancer* 2019; **19**: 450 [PMID: [31088406](#) DOI: [10.1186/s12885-019-5663-8](#)]
- 64 **Ma Z**, Williams M, Cheng YY, Leung WK. Roles of Methylated DNA Biomarkers in Patients with Colorectal Cancer. *Dis Markers* 2019; **2019**: 2673543 [PMID: [30944663](#) DOI: [10.1155/2019/2673543](#)]
- 65 **Hu J**, Zhou Z, Liang J, Zhou H, Wang Z, Zhang X, Zeng W. [Analysis of clinicopathologic and survival characteristics in patients with right-or left-sided colon cancer]. *Zhonghua Yi Xue Za Zhi* 2015; **95**: 2268-2271 [PMID: [26710949](#)]
- 66 **Yang X**, Xu ZJ, Chen X, Zeng SS, Qian L, Wei J, Peng M, Wang X, Liu WL, Ma HY, Gong ZC, Yan YL. Clinical value of preoperative methylated septin 9 in Chinese colorectal cancer patients. *World J Gastroenterol* 2019; **25**: 2099-2109 [PMID: [31114136](#) DOI: [10.3748/wjg.v25.i17.2099](#)]
- 67 **Montagna C**, Lyu MS, Hunter K, Lukes L, Lowther W, Reppert T, Hissong B, Weaver Z, Ried T. The Septin 9 (MSF) gene is amplified and overexpressed in mouse mammary gland adenocarcinomas and human breast cancer cell lines. *Cancer Res* 2003; **63**: 2179-2187 [PMID: [12727837](#)]
- 68 **Gonzalez ME**, Peterson EA, Privette LM, Loffreda-Wren JL, Kalikin LM, Petty EM. High SEPT9_v1 expression in human breast cancer cells is associated with oncogenic phenotypes. *Cancer Res* 2007; **67**: 8554-8564 [PMID: [17875694](#) DOI: [10.1158/0008-5472.CAN-07-1474](#)]
- 69 **Matsui S**, Kagara N, Mishima C, Naoi Y, Shimoda M, Shimomura A, Shimazu K, Kim SJ, Noguchi S. Methylation of the SEPT9_v2 promoter as a novel marker for the detection of circulating tumor DNA in breast cancer patients. *Oncol Rep* 2016; **36**: 2225-2235 [PMID: [27499429](#) DOI: [10.3892/or.2016.5004](#)]

- 70 **Connolly D**, Hoang HG, Adler E, Tazearslan C, Simmons N, Bernard VV, Castaldi M, Oktay MH, Montagna C. Septin 9 amplification and isoform-specific expression in peritumoral and tumor breast tissue. *Biol Chem* 2014; **395**: 157-167 [PMID: [24127542](#) DOI: [10.1515/hsz-2013-0247](#)]
- 71 **Froidevaux-Klipfel L**, Poirier F, Boursier C, Crépin R, Poüs C, Baudin B, Baillet A. Modulation of septin and molecular motor recruitment in the microtubule environment of the Taxol-resistant human breast cancer cell line MDA-MB-231. *Proteomics* 2011; **11**: 3877-3886 [PMID: [21761557](#) DOI: [10.1002/pmic.201000789](#)]
- 72 **Targa B**, Klipfel L, Cantaloube I, Salameh J, Benoit B, Poüs C, Baillet A. Septin filament coalignment with microtubules depends on SEPT9 i1 and tubulin polyglutamylation, and is an early feature of acquired cell resistance to paclitaxel. *Cell Death Dis* 2019; **10**: 54 [PMID: [30670682](#) DOI: [10.1038/s41419-019-1318-6](#)]
- 73 **Cerveira N**, Bizarro S, Teixeira MR. MLL-SEPTIN gene fusions in hematological malignancies. *Biol Chem* 2011; **392**: 713-724 [PMID: [21714766](#) DOI: [10.1515/BC.2011.072](#)]
- 74 **Kojima K**, Sakai I, Hasegawa A, Niiya H, Azuma T, Matsuo Y, Fujii N, Tanimoto M, Fujita S. FLJ10849, a septin family gene, fuses MLL in a novel leukemia cell line CNLBC1 derived from chronic neutrophilic leukemia in transformation with t(4;11)(q21;q23). *Leukemia* 2004; **18**: 998-1005 [PMID: [14999297](#) DOI: [10.1038/sj.leu.2403334](#)]
- 75 **Kreuziger LM**, Porcher JC, Ketterling RP, Steensma DP. An MLL-SEPT9 fusion and t(11;17)(q23;q25) associated with de novo myelodysplastic syndrome. *Leuk Res* 2007; **31**: 1145-1148 [PMID: [17250889](#) DOI: [10.1016/j.leukres.2006.12.006](#)]
- 76 **Kurosu T**, Tsuji K, Ohki M, Miki T, Yamamoto M, Kakihana K, Koyama T, Taniguchi S, Miura O. A variant-type MLL/SEPT9 fusion transcript in adult de novo acute monocytic leukemia (M5b) with t(11;17)(q23;q25). *Int J Hematol* 2008; **88**: 192-196 [PMID: [18642054](#) DOI: [10.1007/s12185-008-0133-0](#)]
- 77 **Santos J**, Cerveira N, Correia C, Lisboa S, Pinheiro M, Torres L, Bizarro S, Vieira J, Viterbo L, Mariz JM, Teixeira MR. Coexistence of alternative MLL-SEPT9 fusion transcripts in an acute myeloid leukemia with t(11;17)(q23;q25). *Cancer Genet Cytogenet* 2010; **197**: 60-64 [PMID: [20113838](#) DOI: [10.1016/j.cancergencyto.2009.10.010](#)]
- 78 **Gulten T**, Yakut T, Karkucak M, Baytan B, Gunes AM. AML1 amplification and 17q25 deletion in a case of childhood acute lymphoblastic leukemia. *J Clin Lab Anal* 2009; **23**: 368-371 [PMID: [19927343](#) DOI: [10.1002/jcla.20343](#)]
- 79 **Cerveira N**, Lisboa S, Correia C, Bizarro S, Santos J, Torres L, Vieira J, Barros-Silva JD, Pereira D, Moreira C, Meyer C, Oliva T, Moreira I, Martins A, Viterbo L, Costa V, Marschalek R, Pinto A, Mariz JM, Teixeira MR. Genetic and clinical characterization of 45 acute leukemia patients with MLL gene rearrangements from a single institution. *Mol Oncol* 2012; **6**: 553-564 [PMID: [22846743](#) DOI: [10.1016/j.molonc.2012.06.004](#)]
- 80 **Forlenza CJ**, Zhang Y, Yao J, Benayed R, Steinherz P, Ramaswamy K, Kessel R, Roshal M, Shukla N. A case of *KMT2A-SEPT9* fusion-associated acute megakaryoblastic leukemia. *Cold Spring Harb Mol Case Stud* 2018; **4** [PMID: [30455225](#) DOI: [10.1101/mcs.a003426](#)]
- 81 **Sørensen AB**, Lund AH, Ethelberg S, Copeland NG, Jenkins NA, Pedersen FS. Sint1, a common integration site in SL3-3-induced T-cell lymphomas, harbors a putative proto-oncogene with homology to the septin gene family. *J Virol* 2000; **74**: 2161-2168 [PMID: [10666245](#) DOI: [10.1128/jvi.74.5.2161-2168.2000](#)]
- 82 **Bennett KL**, Karpenko M, Lin MT, Claus R, Arab K, Dyckhoff G, Plinkert P, Herpel E, Smiraglia D, Plass C. Frequently methylated tumor suppressor genes in head and neck squamous cell carcinoma. *Cancer Res* 2008; **68**: 4494-4499 [PMID: [18559491](#) DOI: [10.1158/0008-5472.CAN-07-6509](#)]
- 83 **Stanbery L**, D'Silva NJ, Lee JS, Bradford CR, Carey TE, Prince ME, Wolf GT, Worden FP, Cordell KG, Petty EM. High SEPT9_v1 Expression Is Associated with Poor Clinical Outcomes in Head and Neck Squamous Cell Carcinoma. *Transl Oncol* 2010; **3**: 239-245 [PMID: [20689765](#) DOI: [10.1593/tlo.10109](#)]
- 84 **Schröck A**, Leisse A, de Vos L, Gevensleben H, Dröge F, Franzen A, Wachendörfer M, Schröck F, Ellinger J, Teschke M, Wilhelm-Buchstab T, Landsberg J, Holdenrieder S, Hartmann G, Field JK, Bootz F, Kristiansen G, Dietrich D. Free-Circulating Methylated DNA in Blood for Diagnosis, Staging, Prognosis, and Monitoring of Head and Neck Squamous Cell Carcinoma Patients: An Observational Prospective Cohort Study. *Clin Chem* 2017; **63**: 1288-1296 [PMID: [28515105](#) DOI: [10.1373/clinchem.2016.270207](#)]
- 85 **Lyu N**, Wang Y, Wang J, Zhang Z, Kong W. Study on early diagnosis of epithelial ovarian cancer by analysis of plasma septin-9 and clusterin level. *J Cancer Res Ther* 2018; **14**: S444-S449 [PMID: [29970704](#) DOI: [10.4103/0973-1482.181178](#)]
- 86 **Scott M**, Hyland PL, McGregor G, Hillan KJ, Russell SE, Hall PA. Multimodality expression profiling shows SEPT9 to be overexpressed in a wide range of human tumours. *Oncogene* 2005; **24**: 4688-4700 [PMID: [15782116](#) DOI: [10.1038/sj.onc.1208574](#)]
- 87 **Powrózek T**, Krawczyk P, Kucharczyk T, Milanowski J. Septin 9 promoter region methylation in free circulating DNA-potential role in noninvasive diagnosis of lung cancer: preliminary report. *Med Oncol* 2014; **31**: 917 [PMID: [24633736](#) DOI: [10.1007/s12032-014-0917-4](#)]
- 88 **Li N**, Wang HL, Liang XP, Yang M. The expression and clinical significance of SEPTIN9 in gastric tissue. *Zhongguo Weichuang Waik Zazhi* 2014; **12**: 1125-1127
- 89 **Song L**, Jia J, Yu H, Peng X, Xiao W, Gong Y, Zhou G, Han X, Li Y. The performance of the mSEPT9 assay is influenced by algorithm, cancer stage and age, but not sex and cancer location. *J Cancer Res Clin Oncol* 2017; **143**: 1093-1101 [PMID: [28224298](#) DOI: [10.1007/s00432-017-2363-0](#)]



Published by Baishideng Publishing Group Inc
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-3991568
E-mail: bpgoffice@wjgnet.com
Help Desk: <https://www.f6publishing.com/helpdesk>
<https://www.wjgnet.com>

